Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Adenosine mediates IL-13–induced inflammation and remodeling in the lung and interacts in an IL-13–adenosine amplification pathway
Michael R. Blackburn, … , Suman K. Banerjee, Jack A. Elias
Michael R. Blackburn, … , Suman K. Banerjee, Jack A. Elias
Published August 1, 2003
Citation Information: J Clin Invest. 2003;112(3):332-344. https://doi.org/10.1172/JCI16815.
View: Text | PDF
Article Immunology Article has an altmetric score of 7

Adenosine mediates IL-13–induced inflammation and remodeling in the lung and interacts in an IL-13–adenosine amplification pathway

  • Text
  • PDF
Abstract

IL-13 is an important mediator of inflammation and remodeling. We hypothesized that adenosine accumulation, alterations in adenosine receptors, and adenosine–IL-13 autoinduction are critical events in IL-13–induced pathologies. To test this, we characterized the effects of IL-13 overexpression on the levels of adenosine, adenosine deaminase (ADA) activity, and adenosine receptors in the murine lung. We also determined whether adenosine induced IL-13 in lungs from ADA-null mice. IL-13 induced an inflammatory and remodeling response that caused respiratory failure and death. During this response, IL-13 caused a progressive increase in adenosine accumulation, inhibited ADA activity and mRNA accumulation, and augmented the expression of the A1, A2B, and A3 but not the A2A adenosine receptors. ADA enzyme therapy diminished the IL-13–induced increase in adenosine, inhibited IL-13–induced inflammation, chemokine elaboration, fibrosis, and alveolar destruction, and prolonged the survival of IL-13–transgenic animals. In addition, IL-13 was strongly induced by adenosine in ADA-null mice. These findings demonstrate that adenosine and adenosine signaling contribute to and influence the severity of IL-13–induced tissue responses. They also demonstrate that IL-13 and adenosine stimulate one another in an amplification pathway that may contribute to the nature, severity, progression, and/or chronicity of IL-13 and/or Th2-mediated disorders.

Authors

Michael R. Blackburn, Chun G. Lee, Hays W.J. Young, Zhou Zhu, Janci L. Chunn, Min Jong Kang, Suman K. Banerjee, Jack A. Elias

×

Figure 13

Options: View larger image (or click on image) Download as PowerPoint
Adenosine-dependent elevations in IL-13 mRNA in lungs from ADA-deficient...
Adenosine-dependent elevations in IL-13 mRNA in lungs from ADA-deficient mice. (a) Whole-lung RNA was extracted from 3-month-old IL-13 Tg mice and 3-week old wild-type and ADA-deficient mice. RT-PCR was used to evaluate the levels of mRNA encoding IL-13 in these samples. (b) Three-week-old ADA-deficient (ADA–/–) mice were treated with a single injection of PEG-ADA, and lung IL-13 mRNA levels were evaluated 72 hours later. IL-13 transcript values are presented as mean nanograms of IL-13 ± SE. n = 5 for each treatment. *P = 0.005. (c) Control and ADA-deficient mice were maintained on ADA enzyme therapy for 3 weeks, and then Alzet pumps containing either theophylline (+ Theo) or saline were implanted. IL-13 mRNA levels were quantitated 12 days later. n = 6 for each treatment. *P = 0.05. nd, not detected.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 25 patents
Highlighted by 1 platforms
Referenced in 1 clinical guideline sources
16 readers on Mendeley
See more details